Amgen posts more promising PCSK9 results; Takeda taps Natrogen for ulcerative colitis drug;

@FierceBiotech: Alimera, pSivida skyrocket as they give the thrice-rejected Iluvien another go. More | Follow @FierceBiotech

@JohnCFierce: Another day, another positive PhIII study for AMG 145 (PCSK9). Release | Follow @JohnCFierce

@DamianFierce: GSK and Theravance score another FDA approval with Anoro, a novel COPD combo therapy. News | Follow @DamianFierce

@EmilyMFierce: BRAIN Initiative announces 6 funding opportunities for biomedical researchers. More from FierceBiotech Research | Follow @EmilyMFierce

> Amgen's ($AMGN) PCSK9-blocking evolocumab met its primary endpoint in top-line results from a Phase III study, lowering LDL cholesterol by 52% after one year. More

> Baxter ($BAX) won FDA approval for Feiba, a prophylaxis treatment designed to reduce bleeding episodes in hemophilia patients who have developed inhibitors to traditional factor-replacement therapy. News

> Takeda has licensed a Phase II ulcerative colitis drug from Deerfield, IL's Natrogen, partnering up on an oral compound that inhibits pro-inflammatory cytokine expression. Release

Medical Device News

@FierceMedDev: Investors propel St. Jude Medical to new heights over 2013 rebound. Article | Follow @FierceMedDev

@MarkHFierce: So, how many device companies will go for FDA/CMS parallel review now that the pilot program has been extended? More | Follow @MarkHFierce

@MichaelGFierce: Synapse collects state-funded $2.4M for next-gen diaphragm pacing device. Item | Follow @MichaelGFierce

@GalenMoore: ICYMI: Despite tax hike, Medtronic's money still flies to Puerto Rico. Story | Follow @GalenMoore

> Decision Diagnostics is raising cash to keep its J&J glucose strip patent fight running. More

Pharma News

@FiercePharma: South Africa's top business daily accuses its state pension fund of protectionism vs. a $1.2B deal with Chile's CFR Pharma. More from Reuters | Follow @FiercePharma

@EricPFierce: AstraZeneca gets former Amylin plant & Bristol-Myers Ohio plant in breakup of diabetes venture. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: As GSK hails its FDA nod for Anoro, a Novartis Advair knockoff prepares for its close-up. Story | Follow @CarlyHFierce

> With a sweetened $2.9B bid, Bayer nabs its Xofigo partner, Algeta. Report

> Bristol-Myers bails out of 'Diabetes Inc.' in $4.1B sell-out to AstraZeneca. Story

> GlaxoSmithKline scores FDA nod for blockbuster COPD hopeful Anoro Ellipta. News

> Raised eyebrows at patient charity spotlight copay assistance debate. More

Pharma Manufacturing News

> Hacked off: Congress members, PhRMA urge an outside audit of the FDA data breach. Story

> Regeneron will invest $300M, hire 300 in its revamp of a Dell plant in Ireland. More

> The FDA and EU members will share some inspection duties. News

> AstraZeneca will take over 2 U.S. plants in its $4.1B diabetes drug transfer. Report

> CEO Nakayama says Daiichi Sankyo is helping Ranbaxy deal with the FDA's concerns. Article

> FDA puts veterinary drugs from banned Wockhardt plants on a leash. Item

Vaccines News

> Schulman leaves Pfizer weeks before start date of new top vaccine job. More

> CDC: Vaccines prevented 6M cases of flu, 79,000 hospitalizations last year. News

> Moderate alcohol consumption acts as vaccine adjuvant in monkeys. Article

> Physician failings raise doubts about the potency of U.K. vaccines. Story

> Agenus stock jumps on Phase II brain cancer vaccine data. Piece

> California calls for unapproved Bexsero to stop its meningitis outbreak. Item

Suggested Articles

It’s been a good year for Intellia: One of its founders, Jennifer Doudna, Ph.D., nabbed the Nobel Prize in Chemistry for her CRISPR research.

After stints at Eli Lilly, Boehringer Ingelheim and Bristol Myers Squibb, Sid Kerkar, M.D., is hopping over to a small biotech.

Two long noncoding RNAs called TROLL-2 and TROLL-3 influence protein signaling to drive the progression of breast cancer, a new study revealed.